drugset / Trial / NCT00585910
Study of Atomoxetine and OROS Methylphenidate to Treat Children and Adolescents Ages 6-17 With ADHD
Phase 4
Completed
94 enrolled
Massachusetts General Hospital
Ortho-McNeil Janssen Scientific Affairs, LLC · collab
NaSingle-groupOpen-labelTreatment
Summary
The purpose of this study is to evaluate the safety, effectiveness, and tolerability of atomoxetine and OROS methylphenidate, taken together, in the treatment of ADHD in children and adolescents ages 6-17.
Timeline
- Start
- 2004-01
- Primary completion
- 2007-12
- Completion
- 2007-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Atomoxetine | Other / unclassified | 1.2 mg/kg | — |
| Subject | Methylphenidate | Small molecule | 54 mg | — |